Sponsors (2)
The bill speeds and clarifies Medicare coverage decisions for FDA‑approved drugs—improving timely patient access and transparency—while raising the likelihood of higher Medicare costs and administrative strain, and imposing a two‑year limit that can delay some NCD reconsiderations.
Medicare beneficiaries (including patients with chronic conditions) gain faster, more predictable access to FDA‑approved drugs and biologics because CMS must initiate and complete a formal NCD review on a set timeline (roughly a 150‑day window from initiation to final decision).
Medicare enrollees in Part D and MA‑PD are less likely to have pharmacy coverage for newly FDA‑approved drugs denied on the basis of outdated pre‑approval NCDs, increasing the chance plans will pay for these therapies.
Patients with newly approved drugs/biologics have stronger protection against coverage denials because coverage decisions are more explicitly aligned with FDA/PHS approvals and licensure.
Taxpayers and Medicare beneficiaries may face higher costs because faster or broader coverage of newly approved drugs could increase Medicare spending and put upward pressure on premiums and Part D formularies.
CMS, state governments, and health systems could experience administrative strain and added implementation costs because mandated, shortened review timelines and new publication requirements may stretch agency capacity and divert resources from other work.
Some patients and advocates may be delayed in obtaining changes to harmful or outdated NCDs because the bill bars successive requester‑initiated reviews for two years, limiting rapid reconsideration.
Based on analysis of 2 sections of legislative text.
Requires time‑limited public review of Medicare NCDs for drugs/biologics and bars pre‑approval NCDs from limiting coverage for newly FDA‑approved drugs/biologics; stops Part D/MA‑PD plans from denying payment on those NCDs.
Official title: To amend title XVIII of the Social Security Act to provide a review process for adverse national coverage determinations with respect to drug coverage under the Medicare program.
Introduced June 24, 2026 by Nanette Barragán · Last progress June 24, 2026
Adds a formal, time‑bound review process for Medicare national coverage determinations (NCDs) for drugs and biological products and prevents pre‑existing NCDs made before FDA approval or PHS licensure from being applied to newly approved drugs/biologics in a way that would deny or limit coverage contrary to the FDA approval or licensure. Also prohibits Medicare Part D and MA‑PD plans from denying payment by relying on those pre‑approval NCDs. Creates deadlines for public initiation, comment, and final decision on specified NCD reviews; requires publication of findings and evidence if a final decision departs from advisory recommendations; and limits repetitive requester-initiated reviews for two years after a decision that affirms, reverses, or modifies a specified NCD.